Connect your AI

Immunome IMNM Increase (decrease) in contract liabilities and current deferred income

Increase (decrease) in contract liabilities and current deferred income at other companies

SPS CommerceSPSC

$4.87M+54.2%

AvePoint, Inc.AVPT

$4.39M+4.3%

Q2 HoldingsQTWO

$45.49M+26.0%

AMN HealthcareAMN

-$4.41M-312%

CalixCALX

$675K-80.6%

Rackspace Technology, Inc.RXT

$35.6M+483%

Other financials

Income statement

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

Market cap$2.24B+323%

Enterprise value$1.66B+470%

P/S557.1×+509×

Profitability

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's increase (decrease) in contract liabilities and current deferred income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Immunome's increase (decrease) in contract liabilities and current deferred income?: Immunome (IMNM) reported increase (decrease) in contract liabilities and current deferred income of -$0 in Q1 2026.
How has Immunome's increase (decrease) in contract liabilities and current deferred income changed year-over-year?: Immunome's increase (decrease) in contract liabilities and current deferred income increased by 100.0% year-over-year, from -$2.93M to -$0.